Biotech

Matching Amgen, Regeneron to Cut List Price of Heart Drug by 60%

Regeneron Pharmaceuticals and partner Sanofi are cutting the list price of their heart drug alirocumab (Praluent) by 60 percent, the latest acknowledgement that the treatment—which has shown a striking ability to lower cholesterol, but has struggled to sell because of its high price tag—isn’t getting to the patients who need it.

Starting in early March, Regeneron (NASDAQ: REGN) and Sanofi (NYSE: SNY) will slash alirocumab’s per year list price from roughly $14,000 to $5,850. The move mirrors an October announcement from Amgen (NASDAQ: AMGN), which also cut the list price of its similar, rival drug evolocumab (Repatha) to… Read more »

UNDERWRITERS AND PARTNERS

          

          

            
https://xconomy.com/new-york/2019/02/11/matching-amgen-regeneron-to-cut-list-price-of-heart-drug-by-60/

Advertisements
READ  Disco-ver These Biotech Jobs

Leave a Reply